Deadline: 18 June 2025
The amfAR is seeking applications for its Target Grant Program aimed at finding a cure for HIV that will be useful to the 40M people living with HIV (PLWH).
The urgency of the goal demands that the organization directs their funding to studies that uncover vital knowledge directly applicable to clinical or pre-clinical cure efforts.
Persistent reservoirs of virus not cleared by antiretroviral therapy represent the main barrier to a cure. amfAR’s Target Grants should focus on pushing the boundaries of biomedical research to achieve sustained HIV remission or complete viral eradication. Priority will be given to clinical or pre-clinical applications studying pragmatic and scalable interventions that can be implemented globally, including in the communities most affected by the epidemic.
The proposed research must be conducted and validated either in vivo (in PLWH, non-human primates, or humanized mice), or ex vivo (in cells isolated from PLWH or infected animals). Interventions tested exclusively in cell lines or in primary cells from HIV-negative individuals will not be considered responsive to this RFP. Submissions that propose only describing the reservoir (i.e., without pre-clinical or clinical interventions) will not be forwarded for review, unless they provide new and critical insights that will meaningfully accelerate HIV cure strategies.
Funding Information
- Award amount: up to $480,000 total costs, including up to 20% indirect costs
- Duration: up to two years duration starting October 1, 2025.
Eligibility Criteria
- Applicants in all countries can apply.
- Applicants should be able to:
- Describe the clinical or pre-clinical intervention they are working towards.
- Articulate the current stage of development of the proposed approach.
- In pre-clinical settings, describe the steps needed to progress to clinical testing.
For more information, visit amfAR.
